

**Mental Health Medication Advisory Committee
Meeting Minutes, Open Session
August 11, 2020 2:00pm – 4:30pm**

<p>Drug Utilization Review Board Due to COVID-19, this meeting was held virtually.</p>	<p>Committee Members: DeAnn Jenkins, MD (Chair) Vishal Adma, MD, MS, CMQ, CPE Holly Cobb, ARNP (absent) Bradley Grinage, MD (absent) Rebecca Klingler, MD Charles Millhuff, DO Karen Moeller, PharmD, BCPP (absent) Taylor Porter, MD Jill Reynoldson, PharmD, BCPP</p> <p>KDHE-DHCF/Contractor Staff: Annette Grant, RPh Victor Nguyen, PharmD Carol Arace, Administrative Specialist</p> <p>MCO Staff: Alan Carter, PharmD, Aetna Better Health of Kansas Janette Mueller, RPh, United Healthcare Community Plan (absent) Angie Yoo, PharmD, Sunflower State Health Plan</p> <p>DXC Staff: Kathy Kaesewurm, RN, BSN Karen Kluczykowski, RPh Harry Vu, PharmD Debbie Bruchko, RN</p>	<p>Public attendees: Billy Randle, Intrust; Chrissy Faulkner, HID; Karen Floeder, Biohaven Pharmaceuticals; Kari Harris, KU School of Med; Kristi Kemp, Allergan; Rachel Brown, KU School of Med.; Ryan Gregg, Ironshore; Susan Zalenski, J&J; Todd Dickerson, Jazz Pharmaceutical; William Warnes, Sunflower Health Plan</p>
---------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TOPIC	DISCUSSION	DECISION
<p>I. Call to Order A. Introductions B. Announcements</p>	<p>Call to Order: Dr. Jenkins called the meeting to order at 2:06 pm. Dr. Jenkins did a roll call of the committee members. Dr. Jenkins asked for any announcements from the State, including any requests for public comment.</p> <p>Announcements: The State thanked everyone for attending and working together. The State also acknowledged that there was at least one commenter from the public.</p>	

TOPIC	DISCUSSION	DECISION
<p>II. Old Business</p> <p>A. Review and Approval of February 11, 2020 Meeting Minutes</p>	<p>Committee Discussion: None.</p>	<p>Dr. Adma motioned to approve. Dr. Porter seconded this motion Motion to approve was carried unanimously.</p>
<p>B. Review and Approval of May 12, 2020 Meeting Minutes</p>	<p>During the review of the May 12, 2020 meeting Dr. Jenkins asked why Dr. Romerein’s name was listed under public attendees. The State pointed out that the Operator listed his name as a member of the public.</p>	<p>Dr. Adma motioned to approve. Dr. Porter approved this motion Motion to approve was unanimous</p>
<p>III. New Business</p> <p>A. Antipsychotic Medications – Safe Use for All Ages</p>	<p>Background: Revision of criteria regarding mood disorder and PTSD with associated severe agitation. Revision of length of approval.</p> <p>Public Comment: None.</p> <p>Committee Discussion: The State shared that there was a request to somewhat broaden the diagnosis for outlier cases, while still providing some safety oversight. Some patients may warrant these drugs for outlier reason, but this may not necessarily be a long-term need. Patient counseling, coping skills, and time can impact the healing process, thus no longer is the medication needed. Other patients may need long-term medication use.</p> <p>Angie Yoo, PharmD and Dr. William Warnes spoke to the need for aggression secondary to a mental health diagnosis to be listed as a need for an antipsychotic, whether it be for short-term or long-term use.</p> <p>After an extended committee discussion on the diagnoses listed and factors considered upon renewal, the committee agreed upon the following PA amendments:</p> <p><u>Provider Type/Diagnosis Section:</u> Child must have a diagnosis of mood disorder, psychotic disorder, Tic disorder (i.e. Tourette’s disorder), Autism Spectrum Disorder, PTSD with associated severe agitation, or have symptoms of severe aggression secondary to mental health diagnosis (hostile or violent behavior directed at oneself or others such as physical aggression or property destruction).</p> <p><u>Renewal Section addition:</u> For patients of all ages, attestation of attempted taper to lowest effective dose.</p>	<p>Dr. Millhuff motioned to approve Dr. Porter seconded the motion Motion approved unanimously</p>

TOPIC	DISCUSSION	DECISION
B. Antidepressant Medications- Safe Use for All Ages	<p>Background: -Addition of step-therapy for select antidepressant products (Aplenzin®, Forfivo XL®, Viibryd®, Trintellix).</p> <p>Public Comment: No Comment</p> <p>Committee Discussion: The State mentioned that currently all four drugs listed are open access, which is not always bad. The State wanted to know the committee members experience with these four products and to present expenditures for these four drugs. The State is spending 32 percent of our dollars for antidepressants on just these four drugs, but they only represent about 2.5 percent of the antidepressant claims. A committee member asked if the state had data showing the number of people who haven't tried the preferred agents and how many people are getting these the first time. The state data presented didn't reflect that aspect. After some discussion, it was proposed and agreed upon that a minimum of 2 generics from the SNRI, SSRI, Tricyclics, MAO Inhibitors, as well as Nefazodone, Mirtazapine, and Bupropion should be tried before these four brand drugs.</p>	<p>Dr. Adma motion for approval for the PA Dr. Porter seconded that motion. The motion was passed unanimously.</p>
C. ADHD Medications- Safe Use for All Ages	<p>Background: Possible addition of criteria regarding multiple concurrent use.</p> <p>Public Comment: Ryan Gregg, Ironshore Pharmaceuticals</p> <p>Committee Discussion: Patient multiple concurrent ADHD drug use was discussed. There is concern regarding normality and commonality of this practice. Deidentified cases were presented for discussion. A decision was made that more clinical information was needed to come to an agreement.</p>	<p>Dr. Porter motioned to table this discussion Dr. Millhuff seconded this motion Unanimous decision to table this discussion.</p>
IV. Open Public Comment	Dr. Rachel Brown and Dr. Kari Harris, KU School of Medicine, presented their KSKidsMAP Program	
V. Adjourn	The meeting adjourned at 4:30pm.	<p>Dr. Porter motioned to adjourn the meeting. Dr. Millhuff seconded this motion. The motion was passed unanimously.</p>

The next MHMAC meeting is scheduled for November 11, 2020.

*All MHMAC approved PA criteria are presented to the DUR Board for final approval. Approved MHMAC PAs are posted to the KDHE website: http://www.kdheks.gov/hcf/pharmacy/pa_criteria.htm